Boston Scientific stock is coming off a difficult stretch, with the share price down 58.1% over the past year, yet the broader valuation checks still lean toward the stock looking inexpensive relative to its fundamentals. That gap between weak recent returns and a stronger value profile is what current and prospective holders are trying to make sense of.

• Over the past 1 year, Boston Scientific has declined 58.1%, which puts recent sentiment under pressure even as longer term holders reassess what the stock is now pricing in.
• For valuation, the key catalyst is whether Boston Scientific can keep growing its minimally invasive device portfolio profitably. At the same time, the recent sterile packaging Class II recalls highlight that quality and regulatory issues may cap how much investors are willing to pay for that growth.
• On Simply Wall St’s broader checks, Boston Scientific screens as undervalued in 5 of 6 areas, suggesting the stock looks cheap on several key measures despite its weak share price performance.

The issue now is whether that high value score reflects a genuine margin of safety in Boston Scientific, or if the share price slide and recent recalls are signaling that the market is correctly marking down the stock.

Does Boston Scientific Look Undervalued on Earnings?

P/E is a useful yardstick for Boston Scientific because the market tends to focus heavily on earnings for established medical equipment companies. The stock currently trades on a P/E of 18.0x, which is well below the Medical Equipment industry average of 26.9x and also below the peer group average of 37.6x. That already points to a sizeable discount relative to sector and peer benchmarks.

On Simply Wall St’s fair P/E estimate of 30.3x, which reflects Boston Scientific’s mix of growth prospects, margins, size and risk, the current 18.0x multiple also sits meaningfully lower. Even with the recent Class II sterile packaging recalls reminding investors of regulatory and quality risk, the market is still pricing Boston Scientific at a level that is considerably under the fair P/E implied by these fundamentals.

Overall, Boston Scientific appears undervalued on a P/E basis, with its earnings multiple sitting well below both industry norms and the modelled fair ratio.

The Boston Scientific Narrative: What Would Justify Today's Price?

Simply Wall St Narratives for Boston Scientific are designed to connect that valuation gap to clear, testable assumptions about Boston Scientific's future growth, margins and earnings, and they sit on the company’s Community page. Each narrative anchors a fair value to a particular mix of potential catalysts and risks, so you can track over time which broad storyline is aligning most closely with how the business and stock actually perform.

One of the top community narratives on Boston Scientific: 56% undervalued

"The immediate impact of the Penumbra acquisition has been somewhat heavy on the stock’s valuation for a few key reasons..."

Do you think there's more to the story for Boston Scientific? Head over to our Community to see what others are saying!

The Bottom Line

For Boston Scientific, the story now is less about the recent share price slide and more about whether the current P/E discount proves justified or temporary. Market multiples suggest the stock screens as undervalued, but that only matters if earnings quality and growth in the minimally invasive device portfolio hold up against regulatory and execution risks raised by the recent recalls. The key question from here is whether that discount is compensating you for real, persistent risk, or whether it eventually narrows as the business proves it can compound profitably without further quality setbacks.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.